Prostate cancer stem cells
Prostate cancer stem cells
复制标题
DOI：
10.1016/j.ejca.2006.01.037
复制
发表时间：
2006-06-01
影响因子：
8.4
通讯作者：
Maitland, Norman J.
中科院分区：
文献类型：
--
作者：
Collins, Anne T.;Maitland, Norman J.
前列腺癌是男性中最常见的癌症。尽管最近在早期前列腺癌的检测方面取得了进展，但对于患有局部晚期和/或转移性疾病的患者几乎没有有效的治疗方法。大多数晚期疾病患者最初对雄激素消融治疗有反应，然而，大多数患者继续发展雄激素非依赖性肿瘤，这些肿瘤不可避免地是致命的。化疗和放疗也有类似的反应。因此，通过目前的治疗策略，转移性前列腺癌仍然是不可治愈的疾病。最近关于癌症干细胞的报道引发了人们对正常干细胞/祖细胞参与前列腺肿瘤生物学、它们对肿瘤本身的潜在贡献以及它们是否是肿瘤发生和进展的原因的疑问。尽管仍存在争议，但癌症干细胞可能是前列腺癌治疗中最关键的靶点，对其生物学的彻底了解，特别是癌症干细胞与正常干细胞的区别，可能会使其被选择性地靶向和消除，从而改善治疗效果。(c)2006爱思唯尔有限公司保留所有权利。
Prostate cancer is the most frequently diagnosed cancer in men. Despite recent advances in the detection of early prostate cancer there is little effective therapy for patients with locally advanced and/or metastatic disease. The majority of patients with advanced disease respond initially to androgen ablation therapy However, most go on to develop androgen-independent tumours that inevitably are fatal. A similar response is seen to chemotherapeutic and radiotherapy treatments. As a result, metastatic prostate cancer remains an incurable disease by current treatment strategies. Recent reports of cancer stem cells have prompted questions regarding the involvement of normal stem/progenitor cells in prostate tumour biology, their potential contribution to the tumour itself and whether they are the cause of tumour initiation and progression. Although still controversial, the cancer stem cell is likely to be the most crucial target in the treatment of prostate cancer, and a thorough understanding of its biology, particularly of how the cancer stem cell differs from the normal stem cell, might allow it to be targeted selectively and eliminated, thus improving therapeutic outcome. (c) 2006 Elsevier Ltd. All rights reserved.